Recombinant Human TIMP-4 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0966NP
BL-0966NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-0966NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human TIMP-4 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0966NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Tissue Inhibitor Of Metalloproteinases 4 is produced by our Mammalian expression system and the target gene encoding Cys30-Pro224 is expressed with a 6His tag at the C-terminus.
Accession Q99727
Synonym Metalloproteinase inhibitor 4; TIMP-4; Tissue inhibitor of metalloproteinases 4; TIMP4
Gene Background Metalloproteinase inhibitor 4 is an enzyme that in humans is encoded by the TIMP4 gene, belongs to the protease inhibitor I35 (TIMP) family. The protein complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9.
Molecular Mass 23.5 KDa
Apmol Mass 24 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9.
Subcellular Location Secreted.
Protein Families Protease inhibitor I35 (TIMP) family
Database References
Tissue Specificity Abundant in heart and present at low levels in many other tissues.

Gene Functions References

  1. MMP2/TIMP4 ratio is a marker of disease severity and right ventricular function as well as a predictor for survival and time to clinical worsening in idiopathic pulmonary arterial hypertension. PMID: 28516393
  2. Aspirin-HPR did not affect the translocation and release of MMPs and TIMP-4 from platelets. PMID: 28770228
  3. Combining two biomarkers significantly improved discrimination of AHRE. CONCLUSION: TIMP-4, NT-proANP, NT-proBNP were strongest associated with PAF and AHRE. The discriminatory performance of CHADS2-VASc for PAF was increased by addition of selected biomarkers. PMID: 28431065
  4. Our findings provide new evidence that LOX regulates SNAI2 expression and that SNAI2-mediated TIMP4 secretion plays a role in cancer progression. PMID: 27029493
  5. This report provides the first example that TIMP-4 regulates carcinogenesis through enriching the tumor progenitor cell population in cervical cancer cells. PMID: 26618609
  6. Concluding, miR-200b-3p mediates regulation of TIMP4 expression in prostate cancer but exact mechanism needs to be investigated. PMID: 28028835
  7. regulates carcinogenesis through apoptosis activation in cervical cancer cells PMID: 26291714
  8. Upregulation of plasma TIMP-4 might contribute to PIH [pregnancy-induced hypertension] processes PMID: 25986893
  9. This study provides evidence that the promoter TIMP4 rs3755724 is a new focal epilepsy susceptibility variant that is plausibly involved in inflammation-induced seizures in Malaysian Chinese. PMID: 25595263
  10. Selective myocardial targeting for TIMP-4 induction through either a viral or transgenic approach favorably altered the course of adverse left ventricular remodeling post-myocardial infarction. PMID: 24637197
  11. The rs3755724 in TIMP4 protein was nominally associated with schizophrenia with poor concentration. PMID: 23229788
  12. Heterogeneous methylation in the promoter region of TIMP4 was associated with cancer progression in non-small cell lung cancer. PMID: 22018271
  13. A trend toward increased serum levels of MMP-9/TIMP-4 was found in patients with successful arteriovenous fistulas. PMID: 21620625
  14. Plasma TIMP-4 has a role in the prediction of LV remodeling and the pathophysiology of the heart postinfarction PMID: 21624734
  15. MMP-10 and -7 abundance increased, accompanied by decreased TIMP-4 in dilated cardiomyopathy failing hearts compared with non-failing hearts. PMID: 20219015
  16. TIMP4 expression is a downstream target of GCM1 PMID: 21406447
  17. Expressions of MMP1, MMP9, TIMP4, and EMMPRIN were significantly unbalanced in the myocardium of congestive heart failure patients with rheumatic heart diseases. PMID: 19734590
  18. this work provides the first evidence of a TIMP-4/CD63 association in astrocytoma tumor cells PMID: 20693981
  19. TIMP-4 overexpression is associated with joint tissue remodeling and pathogenesis of osteoarthritic cartilage PMID: 11948685
  20. TIMP-4 is the major intraplatelet matrix metalloproteinase inhibitor and it is involved in regulation of platelet aggregation and recruitment. PMID: 12466243
  21. Progress curve analysis of MMP inhibition by TIMP-4 indicates that association rate constants and inhibition constants are similar to those for other TIMPs; TIMP-4 has a 5-fold lower binding affinity for proMMP-2 than does TIMP-2. PMID: 12475252
  22. Results suggest a functional relationship between TIMP-4 mRNA and MMP-26 mRNA, and possibly a role in human implantation. PMID: 15273280
  23. TIMP-4 displayed negligible activity against TACE, N-TIMP-4 is a slow tight-binding inhibitor with low nanomolar binding affinity PMID: 15713681
  24. TIMP-4 is expressed de novo in cervical cancer PMID: 15816637
  25. In conclusion, the data demonstrate upregulation of TIMP4 in human cardiovascular disorders exhibiting inflammation, suggesting its future use as a novel systemic marker for vascular inflammation. PMID: 16521002
  26. Maximal expression of TIMP-4 in the early and mid-secretory phase suggests its role during implantation and results show that TIMP-4 control the the relaese of MMP-26 in both stroma and uterine fluid. PMID: 16809379
  27. Results indicate that MMP-26 and TIMP-4 may play an integral role during the conversion of high-grade prostatic intraepithelial neoplasia to invasive cancer and may also serve as markers for early prostate cancer diagnosis. PMID: 16940965
  28. Enzyme immunoassays showed the levels of type 4 tissue inhibitor of metalloproteinases were virtually the same in colorectal cancer and mucosa. PMID: 18214300
  29. C/T polymorphism which is located on the 3'-untranslational regions of the TIMP-4 gene might be associated with susceptibility to Osteoarthritis in a Korean population PMID: 18301898
  30. Peroxynitrite-induced nitration and oligomerization of TIMP-4 attenuated its inhibitory activity against MMP-2 activity and endothelial or tumor cell invasiveness. PMID: 18336787
  31. TIMP4 is related to the development of KD with CALs in Korean children. PMID: 19048177
  32. a cardiopulmonary vasculature-specific role of TIMP-4 activation in systemic sclerosis. PMID: 19190762
  33. MMP-3 and TIMP-4 polymorphisms affect angiographic coronary plaque progression in type 2 diabetic and non-diabetic patients PMID: 19376102
  34. TIMP-4 as a simple prognostic marker that may help identify patients with early-stage breast cancer who could benefit from more aggressive treatment at diagnosis PMID: 19700750

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed